Earnings ·
Evotec reports €465.0m nine-month revenue and reaffirms FY guidance
EVOEvotec SE
Evotec SE reported Group revenue of €465.0 million for the first nine months of 2026, a 13.1% decline from the prior year period, driven by lower sales conversion in its Discovery & Preclinical Development segment and timing impacts at Just – Evotec Biologics. Adjusted Group EBITDA was a loss of €44.3 million, impacted by €91.9 million in reorganization costs associated with the Horizon transformation program. The company reaffirmed its full-year 2026 guidance for revenue between €570 million and €610 million and adjusted EBITDA between -€105 million and -€70 million. Additionally, Evotec announced that Dr. Joanna Holbrook has been appointed Chief Scientific Officer effective November 1, 2026, succeeding Dr. Cord Dohrmann. The company operates in the life sciences sector, providing drug discovery and development services.